ArriVent BioPharma, Inc. (AVBP) · Oct 19, 2026 · Other events
Cancer Cell publication
ArriVent’s Cancer Cell publication adds peer-reviewed validation to firmonertinib’s known PACC lung-cancer results, but brings no new clinical readout.
ArriVent is a clinical-stage biotech building its story around firmonertinib in uncommon EGFR-mutated lung cancer. The drug is already being tested in two pivotal Phase 3 programs—FURVENT for EGFR exon 20 insertions and ALPACCA for PACC mutations—while the company remains pre-revenue and funded by cash and investments rather than product sales.
The filing adds peer-reviewed validation, not a new efficacy event. ArriVent announced publication of the FURTHER Phase 1b results in *Cancer Cell*. The underlying clinical results were already disclosed in 2025, including a 16.0-month median progression-free survival for the 240 mg first-line cohort, so the publication strengthens credibility but does not materially change the known clinical dataset.
The publication supports the rationale for ALPACCA, but does not de-risk the pivotal test. The company says the findings provide a foundation for the global Phase 3 trial and confirms that enrollment continues. 〔0〕 The important unresolved question remains whether firmonertinib can beat investigator-selected osimertinib or afatinib in a controlled first-line comparison—not whether the small Phase 1b dataset is biologically interesting. 〔1〕
Bottom line: This is a modest credibility upgrade to an already-public firmonertinib thesis, not a fresh clinical proof point. It matters mainly as support for the ongoing ALPACCA program; the pivotal trial still determines whether the opportunity becomes a treatment option.
ALPACCA Phase 3 enrollment and comparative readout
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!